Free Trial

Cumberland Pharmaceuticals (CPIX) Competitors

Cumberland Pharmaceuticals logo
$3.22 -0.49 (-13.21%)
Closing price 04:00 PM Eastern
Extended Trading
$3.52 +0.30 (+9.32%)
As of 07:52 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

CPIX vs. OMER, ASMB, LLY, JNJ, ABBV, MRK, PFE, BMY, ZTS, and RPRX

Should you be buying Cumberland Pharmaceuticals stock or one of its competitors? The main competitors of Cumberland Pharmaceuticals include Omeros (OMER), Assembly Biosciences (ASMB), Eli Lilly and Company (LLY), Johnson & Johnson (JNJ), AbbVie (ABBV), Merck & Co., Inc. (MRK), Pfizer (PFE), Bristol Myers Squibb (BMY), Zoetis (ZTS), and Royalty Pharma (RPRX). These companies are all part of the "pharmaceuticals" industry.

Cumberland Pharmaceuticals vs. Its Competitors

Cumberland Pharmaceuticals (NASDAQ:CPIX) and Omeros (NASDAQ:OMER) are both small-cap medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their earnings, risk, media sentiment, institutional ownership, profitability, analyst recommendations, valuation and dividends.

In the previous week, Cumberland Pharmaceuticals had 15 more articles in the media than Omeros. MarketBeat recorded 20 mentions for Cumberland Pharmaceuticals and 5 mentions for Omeros. Omeros' average media sentiment score of 1.12 beat Cumberland Pharmaceuticals' score of -0.19 indicating that Omeros is being referred to more favorably in the news media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Cumberland Pharmaceuticals
0 Very Positive mention(s)
3 Positive mention(s)
10 Neutral mention(s)
3 Negative mention(s)
4 Very Negative mention(s)
Neutral
Omeros
1 Very Positive mention(s)
0 Positive mention(s)
1 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive

15.5% of Cumberland Pharmaceuticals shares are owned by institutional investors. Comparatively, 48.8% of Omeros shares are owned by institutional investors. 44.9% of Cumberland Pharmaceuticals shares are owned by company insiders. Comparatively, 12.9% of Omeros shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

Omeros has a consensus price target of $18.00, indicating a potential upside of 435.71%. Given Omeros' stronger consensus rating and higher probable upside, analysts clearly believe Omeros is more favorable than Cumberland Pharmaceuticals.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Cumberland Pharmaceuticals
0 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
0.00
Omeros
0 Sell rating(s)
2 Hold rating(s)
3 Buy rating(s)
1 Strong Buy rating(s)
2.83

Cumberland Pharmaceuticals has a beta of -0.39, indicating that its stock price is 139% less volatile than the S&P 500. Comparatively, Omeros has a beta of 2.16, indicating that its stock price is 116% more volatile than the S&P 500.

Omeros has a net margin of 0.00% compared to Cumberland Pharmaceuticals' net margin of -7.98%. Cumberland Pharmaceuticals' return on equity of 6.92% beat Omeros' return on equity.

Company Net Margins Return on Equity Return on Assets
Cumberland Pharmaceuticals-7.98% 6.92% 2.33%
Omeros N/A N/A -59.68%

Cumberland Pharmaceuticals has higher revenue and earnings than Omeros. Cumberland Pharmaceuticals is trading at a lower price-to-earnings ratio than Omeros, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Cumberland Pharmaceuticals$37.87M1.27-$6.48M-$0.25-12.88
OmerosN/AN/A-$156.82M-$2.65-1.27

Summary

Omeros beats Cumberland Pharmaceuticals on 9 of the 16 factors compared between the two stocks.

Get Cumberland Pharmaceuticals News Delivered to You Automatically

Sign up to receive the latest news and ratings for CPIX and its competitors with MarketBeat's FREE daily newsletter.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding CPIX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

CPIX vs. The Competition

MetricCumberland PharmaceuticalsMED IndustryMedical SectorNASDAQ Exchange
Market Cap$55.51M$2.73B$5.52B$9.41B
Dividend YieldN/A1.79%3.80%4.04%
P/E Ratio-12.888.9428.0419.84
Price / Sales1.27697.47429.5399.59
Price / Cash14.42161.2635.8457.94
Price / Book2.005.008.125.65
Net Income-$6.48M$30.99M$3.25B$258.00M
7 Day Performance7.33%1.69%0.97%2.09%
1 Month Performance-39.93%9.20%7.36%11.13%
1 Year Performance123.61%-1.25%31.31%18.40%

Cumberland Pharmaceuticals Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
CPIX
Cumberland Pharmaceuticals
0.8866 of 5 stars
$3.22
-13.2%
N/A+152.4%$55.51M$37.87M-12.8880Trending News
OMER
Omeros
3.7837 of 5 stars
$3.08
-3.8%
$18.00
+484.4%
-33.1%$187.50MN/A-1.16210Positive News
Analyst Revision
Gap Up
ASMB
Assembly Biosciences
3.7919 of 5 stars
$18.56
+2.3%
$33.00
+77.8%
+27.1%$138.55M$32.15M-2.98100Trending News
LLY
Eli Lilly and Company
4.979 of 5 stars
$772.82
-1.0%
$1,011.61
+30.9%
-15.8%$739.87B$45.04B62.8847,000Trending News
JNJ
Johnson & Johnson
4.7823 of 5 stars
$155.23
-0.5%
$170.88
+10.1%
+4.1%$375.37B$88.82B17.27138,100Trending News
Earnings Report
Dividend Announcement
Analyst Forecast
Options Volume
Analyst Revision
ABBV
AbbVie
4.7838 of 5 stars
$187.44
-1.0%
$211.29
+12.7%
+9.1%$334.34B$56.33B79.7655,000Trending News
Ex-Dividend
Analyst Revision
MRK
Merck & Co., Inc.
4.9955 of 5 stars
$80.89
0.0%
$109.19
+35.0%
-35.2%$203.22B$64.17B11.7775,000Positive News
PFE
Pfizer
4.9618 of 5 stars
$25.23
-0.6%
$28.55
+13.2%
-18.1%$144.29B$62.46B18.2881,000Trending News
BMY
Bristol Myers Squibb
4.8953 of 5 stars
$46.50
-0.9%
$58.00
+24.7%
+11.4%$95.49B$47.64B17.4234,100Trending News
Analyst Revision
ZTS
Zoetis
4.9604 of 5 stars
$156.98
-1.4%
$212.13
+35.1%
-17.6%$70.87B$9.26B28.1813,800Trending News
Analyst Downgrade
Analyst Revision
RPRX
Royalty Pharma
4.9716 of 5 stars
$35.59
-2.1%
$47.33
+33.0%
+26.2%$20.45B$2.26B19.2480News Coverage
Positive News
Dividend Announcement

Related Companies and Tools


This page (NASDAQ:CPIX) was last updated on 7/18/2025 by MarketBeat.com Staff
From Our Partners